Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a Sell.

A month has gone by since the last earnings report for Steris. Shares have lost about 1.8% in that time frame, ...

Pacific Biosciences of California ... Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing ...

Steris is part of the Zacks Medical - Instruments industry. Over the past month, Pacific Biosciences of California (PACB), a stock from the same industry, has gained 11.3%. The company reported ...

The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance ...

It is anticipated that the global biomarker testing market will experience rapid growth, with a valuation of approximately USD 122.8 billion by 2033, and a compound annual growth rate (CAGR) of 10.4% ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to ...